|
SELECT PUBLICATIONS
Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med 2005;353:1652-4. No abstract available
Buzdar AU et al. Significantly higher pathologic complete response remission rate after
neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy:
Results of a randomized trial in human epidermal growth factor receptor 2-positive
operable breast cancer. J Clin Oncol 2005;23:3656-59. Abstract
Cobleigh MA et al. Multinational study of the efficacy and safety of humanized anti-
HER-2 monoclonal antibody in women who have HER2-overexpressing metastatic
breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48. Abstract
De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A
paradigmatic shift of drug development in oncology. Ann Oncol 2005;(16 Suppl 4):iv7-iv13.
Abstract
Dowsett M et al. Retrospective analysis of time to recurrence in the ATAC trial
according to hormone receptor status: A hypothesis-generating study. J Clin Oncol 2005;23(30):7512-17. Abstract
Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-6. No abstract available
Perez EA. NCCTG-N9831: May 2005 update. Presentation. ASCO 2005. No abstract available
Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection
fraction in patients with breast cancer in the North Central Cancer Treatment Group
N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(18):3700-4. Abstract
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med 2005;353:1659-72. Abstract
Pietras RJ et al. Remission of human breast cancer xenografts on therapy with humanized
monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-49. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive
breast cancer. N Engl J Med 2005;353:1673-84. Abstract
Slamon DJ. Antibody-based therapeutics: More than a one-trick pony. Presentation. ASCO
2005. No abstract available
Slamon DJ et al. Human breast cancer: Correlation of relapse and survival with amplification
of the HER-2/neu oncogene. Science 1987;235(4785):177-82. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing
doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab
as adjuvant therapy in node-positive, human epidermal growth factor receptor
2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-19. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment
of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26.
Abstract
Willems A et al. Antibody therapy for breast cancer. Anticancer Res 2005;25(3A):1483-9.
Abstract
|
